Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Left-Sided Intracardiac Tumors in a Case of Widespread Vulvar Cancer.

JACC. Case reports·2021

Same author

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients.

JACC. Case reports·2021

Same author

The concoction of cancer, catheter, and intracardiac clot: a case report describing a potential treatment strategy.

European heart journal. Case reports·2020

Same author

Cardiac papillary fibroelastoma originating from the coumadin ridge and review of literature.

BMJ case reports·2020

Same author

Metastatic Melanoma Presenting as a Ventricular Arrhythmia.

Cureus·2020

Same author

Simultaneous Multifocal Paradoxical Embolism in an Elderly Patient with Patent Foramen Ovale: A Case Report.

Cureus·2020

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

PPARgamma agonists: safety issues in heart failure.

W H Wilson Tang¹, Anjli Maroo

¹Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH 44195, USA. tangw@ccf.org

Diabetes, Obesity & Metabolism

|June 26, 2007

Summary

Thiazolidinediones (TZDs) effectively manage diabetes but can cause fluid retention, particularly in heart failure patients. While generally safe for mild heart failure, further research into TZD mechanisms is needed.

Related Experiment Videos

Last Updated: Jul 14, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Area of Science:

Endocrinology
Cardiology
Pharmacology

Background:

PPARgamma agonists, known as thiazolidinediones (TZDs), are widely used for glycemic control in diabetes mellitus.
Clinical data indicate potential side effects including fluid retention, edema, and congestive heart failure, raising safety concerns in patients with pre-existing heart conditions.

Purpose of the Study:

To review the safety and efficacy of TZDs in diabetic patients, with a focus on fluid retention and heart failure.
To evaluate the hemodynamic effects and clinical implications of TZD-induced fluid retention.

Main Methods:

Literature review of clinical trials, registries, and published studies on TZD use in diabetic patients.
Analysis of reported side effects, particularly fluid retention, edema, and congestive heart failure.
Assessment of TZD safety in patients with varying degrees of heart failure (NYHA class I-II).

Main Results:

TZDs are generally associated with sub-acute, peripheral fluid retention developing over weeks to months, often resolving upon drug withdrawal.
Existing literature suggests TZDs do not typically cause adverse hemodynamic consequences.
Current evidence supports the use of TZDs in patients with mild, stable heart failure (NYHA class I-II).

Conclusions:

TZD use is considered acceptable in mild, stable heart failure, with fluid retention being a manageable side effect.
Emerging data suggest potential benefits of TZDs in diabetic populations, irrespective of heart failure status.
Further research is warranted to elucidate the mechanisms of TZD-induced sodium retention and vascular permeability, and to develop safer TZD analogs.